+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Epilepsy Drugs Market 2020-2024

  • PDF Icon

    Report

  • 120 Pages
  • November 2020
  • Region: Global
  • TechNavio
  • ID: 5205129
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Epilepsy Drugs Market 2020-2024

The publisher has been monitoring the epilepsy drugs market and it is poised to grow by $ 2.13 bn during 2020-2024 progressing at a CAGR of 5% during the forecast period. The reports on epilepsy drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of epilepsy and increasing patient awareness. In addition, increasing prevalence of epilepsy is anticipated to boost the growth of the market as well.

The epilepsy drugs market analysis includes the type segment, etilogy segment, age of onset segment and geographical landscapes.

The epilepsy drugs market is segmented as below:

By Type
  • Narrow spectrum drugs
  • Broad spectrum drugs

By Etiology
  • Genetic etiology
  • Structural etiology
  • Metabolic etiology
  • Immune etiology
  • Infectious etiology
  • Unknown etiology

By Age of onset
  • Neonatal/infantile
  • Childhood
  • Adolescents/adults
  • Variable age

By Geographical Landscapes
  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing use of specific and sensitive diagnostic modalities as one of the prime reasons driving the epilepsy drugs market growth during the next few years.

The epilepsy drugs market covers the following areas:
  • Epilepsy drugs market sizing
  • Epilepsy drugs market forecast
  • Epilepsy drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epilepsy drugs market vendors that include Abbott Laboratories, Eisai Co. Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Mylan NV, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and UCB SA. Also, the epilepsy drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type
  • Market segments
  • Comparison by Type
  • Narrow spectrum drugs - Market size and forecast 2019-2024
  • Broad spectrum drugs - Market size and forecast 2019-2024
  • Market opportunity by Type

Segmentation by Etiology
  • Genetic etiology
  • Structural etiology
  • Metabolic etiology
  • Immune etiology
  • Infectious etiology
  • Unknown etiology

Segmentation by Age of Onset
  • Neonatal/infantile
  • Childhood
  • Adolescents/adults
  • Variable age

Customer landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Vendor landscape
  • Landscape disruption
  • Competitive Scenario

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • Eisai Co. Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2019 - 2024 ($ million)
  • Global market: Year-over-year growth 2019 - 2024 (%)
  • Five forces analysis 2019 & 2024
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2019
  • Type - Market share 2019-2024 (%)
  • Comparison by Type
  • Narrow spectrum drugs - Market size and forecast 2019-2024 ($ million)
  • Narrow spectrum drugs - Year-over-year growth 2019-2024 (%)
  • Broad spectrum drugs - Market size and forecast 2019-2024 ($ million)
  • Broad spectrum drugs - Year-over-year growth 2019-2024 (%)
  • Market opportunity by Type
  • Customer landscape
  • Market share by geography 2019-2024 (%)
  • Geographic comparison
  • North America - Market size and forecast 2019-2024 ($ million)
  • North America - Year-over-year growth 2019-2024 (%)
  • Europe - Market size and forecast 2019-2024 ($ million)
  • Europe - Year-over-year growth 2019-2024 (%)
  • Asia - Market size and forecast 2019-2024 ($ million)
  • Asia - Year-over-year growth 2019-2024 (%)
  • ROW - Market size and forecast 2019-2024 ($ million)
  • ROW - Year-over-year growth 2019-2024 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Key customers
  • Abbott Laboratories - Segment focus
  • Eisai Co. Ltd. - Overview
  • Eisai Co. Ltd. - Business segments
  • Eisai Co. Ltd. - Key offerings
  • Eisai Co. Ltd. - Key customers
  • Eisai Co. Ltd. - Segment focus
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Key customers
  • GlaxoSmithKline Plc - Segment focus
  • Johnson & Johnson - Overview
  • Johnson & Johnson - Business segments
  • Johnson & Johnson - Key offerings
  • Johnson & Johnson - Key customers
  • Johnson & Johnson - Segment focus
  • Mylan NV - Overview
  • Mylan NV - Business segments
  • Mylan NV - Key offerings
  • Mylan NV - Key customers
  • Mylan NV - Segment focus
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key offerings
  • Novartis AG - Key customers
  • Novartis AG - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • Sanofi - Overview
  • Sanofi - Business segments
  • Sanofi - Key offerings
  • Sanofi - Key customers
  • Sanofi - Segment focus
  • Teva Pharmaceutical Industries Ltd. - Overview
  • Teva Pharmaceutical Industries Ltd. - Business segments
  • Teva Pharmaceutical Industries Ltd. - Key offerings
  • Teva Pharmaceutical Industries Ltd. - Key customers
  • Teva Pharmaceutical Industries Ltd. - Segment focus
  • UCB SA - Overview
  • UCB SA - Product and service
  • UCB SA - Key offerings
  • UCB SA - Key customers
  • UCB SA - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global epilepsy drugs market: Abbott Laboratories, Eisai Co. Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Mylan NV, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and UCB SA.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is growing use of specific and sensitive diagnostic modalities.'

According to the report, one of the major drivers for this market is the increasing prevalence of epilepsy.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Eisai Co. Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA